NAD+

ASSUMED mechanism: NAD+ is an essential coenzyme for mitochondrial ATP production, redox reactions, and as a substrate for DNA-repair enzymes (PARPs) and sirtuins; tissue NAD+ falls with age, so the theory is that injecting NAD+ replenishes it. The human PK data complicate this: infused NAD+ is rapidly cleared and substantially cleaved to nicotinamide and ADP-ribose extracellularly, meaning cells likely take up the breakdown products and resynthesize NAD+ internally rather than importing intact NAD+. So even if benefits occur, the proposed 'direct cellular refill' picture is largely assumed and partly contradicted by the data.

Grades count randomized human trials whether they worked or not. The blood-level trials are lab surrogates, one is a preprint with an industry-linked sponsor, and none tests energy, clarity or longevity. The heart-failure trial is a disease population.

Adverse events

Most common: rate-dependent infusion reactions, flushing, warmth, chest pressure/tightness, nausea, abdominal cramping, vomiting, diarrhea, racing heart, throat discomfort, headache, dizziness. In one pilot, 100% of IV NAD+ recipients had moderate-to-severe symptoms during the drip; symptoms typically resolve within minutes of stopping/slowing. No deaths or serious organ injury were reported in the small published cohorts; liver enzymes and kidney function stayed stable acutely. Separately, FDA documented patients with shaking and low blood pressure after a contaminated compounded lot (endotoxin 3,360 EU/mL), which led to a Class I recall. That is a product-quality failure, not a property of the molecule, but it is the main real-world risk.

Contraindications

Reported screening exclusions in clinic practice (not formally validated): pregnancy/breastfeeding, severe cardiovascular disease, G6PD deficiency, active cancer, and known hypersensitivity. Because product is compounded and not FDA-approved, sterility and purity depend entirely on the pharmacy/source; food-grade NAD+ used for IV has been flagged by FDA for contamination risk.

Theoretical concerns

Infused NAD+ is largely cleaved to nicotinamide before cellular uptake, and high nicotinamide loads can in theory deplete methyl groups (methylation stress) and inhibit sirtuins/PARPs at high concentration. One acute RCT flagged a rise in white blood cells/neutrophils with IV NAD+, a possible pro-inflammatory signal of uncertain meaning. Boosting NAD+ salvage is also theoretically a concern in active malignancy (some tumors are NAD-avid), though this is unproven in humans.

What nobody knows yet

No long-term safety data of any kind for repeated injectable NAD+ dosing. No data on cumulative methylation burden, chronic immune/inflammatory effects, cancer interactions, or cardiovascular outcomes. Subcutaneous/IM pharmacokinetics in humans are essentially uncharacterized in the peer-reviewed literature, bioavailability and tissue delivery via those routes are assumed, not measured.

What else could explain the result

IV NAD+ is almost always delivered with a bag of saline (hydration alone improves how people feel), often alongside B-vitamins, glutathione, magnesium, vitamin C, or amino-acid 'cocktails' in clinic drips. Many users also start it during a broader lifestyle reset (sobriety, sleep fixes, fasting, new supplements), and the expensive, ritualized clinic setting itself primes a strong expectancy effect, all of which muddy attribution to NAD+ itself.

Is the vial what it says?

Cross-checked across a 2019 PK pilot (PMC6751327), a 2024 randomized placebo-controlled acute pilot (NCT06382688), a 2025-2026 retrospective tolerability pilot (PMC12907335), PRISMA/systematic reviews, and regulatory/FDA compounding guidance. Findings are strikingly consistent: IV NAD+ exists and is broadly survivable but is largely degraded en route, less efficient and less tolerable than IV NR, and unsupported by any anti-aging or wellness outcome RCT; the one outcomes trial (Yu 2026, heart failure, 10 mg a day) is a disease surrogate. Note: the strongest head-to-head dataset comes from the NR supplement-industry sphere, so its 'NR is superior' framing is an interested conclusion, but the underlying data on injectable NAD+ are independent of that spin.

Half-life and storage

Half-life: Intact NAD+ is cleared from plasma very rapidly, essentially undetectable rise for the first ~2 hours of a slow infusion, consistent with fast extracellular breakdown. Its principal metabolite nicotinamide has a dose-dependent half-life of roughly 1.5 hours (1 g) up to 7-9 hours at very high doses. Net effect: any plasma NAD+ bump from injection is short-lived and overshadowed by metabolite kinetics.

Once mixed: NAD+ is supplied as a sterile compounded solution or a lyophilized powder requiring reconstitution; it is moisture- and heat-sensitive and degrades over time, so vials are kept refrigerated, protected from light, and used promptly after reconstitution. Sterility is paramount for an injectable. FDA has specifically warned against food-grade NAD+ in IV preparations because of contamination/adverse-event risk; quality is only as good as the compounding source.

What people report

Volume of reports: moderate. A real body of reports, fairly consistent.

High volume. NAD+ drips/injections are among the most heavily marketed and discussed wellness 'biohacks,' with abundant clinic testimonials, influencer accounts, and recovery-community reports, but the conversation is dominated by clinics and vendors selling the service, so raw volume overstates independent signal.

Moderately consistent on themes, most reports cluster around subjective 'energy,' mental clarity, reduced brain fog, mood lift, and (in recovery settings) reduced cravings/withdrawal discomfort. But reports are equally consistent about the unpleasant during-infusion symptoms, and a meaningful minority describe little or no lasting effect once the novelty/hydration wears off.

Low-to-moderate credibility. The overwhelming majority of positive sources are IV clinics, med-spas, and compounding/supplement vendors with a direct financial interest, and the most-cited head-to-head trial sits in the NR supplement-industry sphere. Independent, disinterested user reports exist but are diluted by affiliate/marketing content, so the anecdotal signal is heavily discounted.

• Many users report a noticeable lift in energy, mental clarity, and reduced brain fog in the days after a session, though some say the effect fades within days to a couple of weeks (anecdotal, not proof).
• A very common refrain is that the infusion itself feels rough: chest pressure/tightness, nausea, cramping, and a racing heart, which people describe as the hardest part of the infusion (anecdotal).
• In addiction-recovery communities, users often credit IV NAD+ with easing withdrawal symptoms, cravings, and mood during early sobriety, frequently as part of a broader treatment program, which confounds attribution (anecdotal).
• A skeptical contingent reports little durable benefit beyond feeling hydrated and 'pampered,' and questions whether the high per-session cost justifies effects they suspect are largely placebo (anecdotal).

Reports are anecdote, not proof.

Can you tell if it is working?

First documented human use: First documented human use: 1961, Dr. Paul O'Hollaren (Shadel Hospital, Seattle) reported IV NAD+ in over 100 cases of substance addiction (alcohol, opioids, stimulants, barbiturates), an uncontrolled case series, not a trial. No randomized trial of injectable NAD+ has tested an anti-aging or wellness outcome. One 180-patient placebo-controlled trial in ischemic heart failure (10 mg IV daily for 7 days) improved ejection fraction at one month, and the other randomized work is small acute pharmacokinetic and tolerability pilots.

1. 1961Dr. Paul O'Hollaren (Shadel Hospital, Seattle) publishes an uncontrolled case series using IV NAD+ in 100+ addiction cases; notes headache and shortness of breath at faster drip rates, the first description of rate-dependent infusion reactions.
2. 2010sIV NAD+ ('NAD therapy', 'the NAD drip') spreads through addiction-recovery and concierge wellness clinics; aggressive longevity/energy marketing despite no controlled outcome data.
3. 2019Grant et al. pilot PK study (n=11) shows infused NAD+ is cleared from plasma for the first 2 hours and largely metabolized to nicotinamide and ADP-ribose, the first hard human evidence that IV NAD+ is mostly broken down, not delivered intact.
4. 2024First randomized, placebo-controlled acute pilot (NCT06382688) directly compares IV NAD+ to IV NR: NAD+ raises blood NAD+ less, is less tolerable, slower to infuse, and shows a WBC/neutrophil rise.
5. 2025-2026Retrospective tolerability pilot and PRISMA-guided reviews reaffirm: every IV NAD+ patient had moderate-to-severe infusion symptoms, and controlled OUTCOME evidence for anti-aging/wellness remains absent.
6. Jul-Oct 2025A compounder begins a voluntary recall of NAD+ injection on Jul 30 2025; in October 2025 FDA classifies it Class I for elevated endotoxin.
7. Sep 2025 / Jan 2026Yu et al. publish a 180-patient randomized placebo-controlled trial of IV NAD+ (10 mg a day for 7 days) in ischemic heart failure: ejection fraction improves at one month. The first outcomes RCT of injectable NAD+, in a disease population.
8. Jan 20 2026FDA warning letter to an NAD+ compounder states NAD+ is not on the 503B bulks list.

• Grant et al. (2019). Human plasma & urine NAD+ metabolome during 6-h IV NAD+ infusion (PMC6751327)(Foundational human PK pilot (n=11): infused NAD+ cleared from plasma for first 2 h and largely cleaved to nicotinamide/ADP-ribose. Best evidence that IV NAD+ is mostly degraded en route.)
• Acute randomized placebo-controlled pilot: IV NR vs IV NAD+ vs oral NR vs saline (NCT06382688)(Acute RCT directly testing IV NAD+ (53 participants, preprint only: doi 10.1101/2024.06.06.24308565). Surrogate endpoint (blood NAD+), not clinical outcome; IV NAD+ less effective/less tolerable than NR, with a WBC/neutrophil rise. Industry-adjacent, read framing critically.)
• IV NAD+ vs NR retrospective tolerability pilot, Frontiers in Aging (PMC12907335)(Real-world pilot: 100% of IV NAD+ recipients had moderate-to-severe infusion symptoms; ~97 min infusions. Small, retrospective.)
• Gallagher and Emmanuel, Ageing Res Rev 2026 (PMID 41655607)(PRISMA review of 113 studies: no eligible outcomes trials of IV or IM NAD+ for anti-aging or wellness; effectiveness for those uses is inconclusive.)
• Yu et al., Am J Cardiovasc Drugs 2026 (PMID 40954388)(180-patient placebo-controlled RCT of IV NAD+ 10 mg a day for 7 days in ischemic cardiomyopathy; LVEF higher at one month (p=0.024). Single-center, surrogate endpoint, disease population.)
• FDA: compounders must use ingredients suitable for sterile compounding (NAD+)(Injectable NAD+ is not FDA-approved. FDA has warned against food-grade NAD+ for IV use (contamination/AE risk).)
• FDA warning letter 718739 to an NAD+ compounder, Jan 20 2026(States NAD+ is not on the 503B bulks list; documents an endotoxin-contaminated lot and a Class I recall.)
• Yu X et al. Am J Cardiovasc Drugs 2026;26(1), online Sept 15, 2025. PMID 40954388(dose table)
• Grant R et al. 2019, pilot study of the human plasma and urine NAD+ metabolome during a 6 h IV NAD+ infusion. PMC6751327(dose table)
• ClinicalTrials.gov NCT06382688 (no results posted); data in medRxiv preprint 10.1101/2024.06.06.24308565(dose table)